8-K filing — Aptevo Therapeutics Inc. (APVO)
Filed: 2026-08-14 AccNo: 0001193125-26-350537 Size: 210 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 12:32 PM
- Checked
- Aug 14, 2026, 12:32 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously
Read original at benzingaAptevo Therapeutics shares are trading lower. The company announced exercise of existing warrants and PIPE for $4.5 million gross proceeds.
Read original at benzinga